Related Experiment Video

Updated: May 6, 2026

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach
11:11

Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach

Published on: February 21, 2019

7.1K

Protein kinase C (PKC) as a drug target in chronic lymphocytic leukemia

Julhash U Kazi1, Nuzhat N Kabir, Lars Rönnstrand

  • 1Translational Cancer Research, Lund University, Medicon Village, Building 404:C3, 223 63, Lund, Sweden, Kazi.Uddin@med.lu.se.

Medical Oncology (Northwood, London, England)
|November 1, 2013
PubMed

Insights

Protein kinase C (PKC) signaling is crucial in chronic lymphocytic leukemia (CLL) pathogenesis. Targeting specific PKC isoforms offers a promising therapeutic strategy for this heterogeneous hematological malignancy.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Protein kinase C (PKC) is a family of serine/threonine kinases involved in critical cellular processes like proliferation, survival, differentiation, and apoptosis.
  • PKC isoforms exhibit distinct signaling characteristics due to differential subcellular localization and tissue distribution.
  • Chronic lymphocytic leukemia (CLL) is a heterogeneous hematological disorder with variable patient survival.

Purpose of the Study:

  • To review the roles of Protein kinase C (PKC) family members in the pathogenesis of chronic lymphocytic leukemia (CLL).
  • To highlight the differential expression and functional significance of PKC isoforms in CLL.
  • To explore the potential of isoform-specific PKC inhibitors as a therapeutic approach for CLL.

Main Methods:

  • Literature review of studies investigating PKC family members and their roles in CLL.
  • Analysis of data on differential expression patterns of PKC isoforms in CLL patients.
  • Synthesis of information on the impact of PKC signaling on CLL pathogenesis.

Main Results:

  • PKC isoforms are differentially expressed in CLL, indicating specific roles in the disease.
  • PKC signaling pathways are implicated in key aspects of CLL pathogenesis, including cell survival and proliferation.
  • The distinct functions of PKC isoforms suggest potential for targeted therapeutic interventions.

Conclusions:

  • Protein kinase C (PKC) isoforms play significant roles in the development and progression of chronic lymphocytic leukemia (CLL).
  • Targeting specific PKC isoforms, rather than the entire family, presents a viable and attractive therapeutic strategy for CLL treatment.
  • Further research into isoform-specific PKC inhibitors could lead to novel treatments for CLL.

More Related Videos

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia09:52

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia

Published on: December 4, 2018

7.2K
A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English14:34

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

331

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.1K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
7.3K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
129